Inflammation, Immunity, and Hypertensive End-Organ Damage

Circulation Research

Volumn 116, Issue 6, 2015, Pages 1022-1033

  McMaster, William G ^a,b   Kirabo, Annet ^b   Madhur, Meena S ^b   Harrison, David G ^b  

^a Division of Clinical Pharmacology   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

angiotensin II; antigen presenting cell; cytokines; effector T cell; nitric oxide synthase; sodium

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; 2-(AMINOMETHYL)PHENOL; BENZYLAMINE DERIVATIVE; CYTOKINE; REACTIVE OXYGEN METABOLITE;

BLOOD PRESSURE; END ORGAN DAMAGE; HISTORY OF MEDICINE; HUMAN; HYPERTENSION; IMMUNE SYSTEM; IMMUNITY; INFLAMMATION; NONHUMAN; ORGAN INJURY; OXIDATIVE STRESS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE ACTIVATION; ADAPTIVE IMMUNITY; ANIMAL; ANIMAL MODEL; ARTERIAL STIFFNESS; BIOLOGICAL MODEL; CARDIOVASCULAR DISEASES; DEFICIENCY; IMMUNOLOGY; INNATE IMMUNITY; KIDNEY; KNOCKOUT MOUSE; LYMPHOCYTE ACTIVATION; METABOLISM; MOUSE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PRECLINICAL STUDY; SIGNAL TRANSDUCTION; T LYMPHOCYTE SUBPOPULATION; VASCULAR REMODELING;

ADAPTIVE IMMUNITY; ANIMALS; BENZYLAMINES; CARDIOVASCULAR DISEASES; CYTOKINES; DRUG EVALUATION, PRECLINICAL; HUMANS; HYPERTENSION; IMMUNITY, INNATE; INFLAMMATION; KIDNEY; LYMPHOCYTE ACTIVATION; MICE; MICE, KNOCKOUT; MODELS, ANIMAL; MODELS, CARDIOVASCULAR; MODELS, IMMUNOLOGICAL; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; T-LYMPHOCYTE SUBSETS; VASCULAR REMODELING; VASCULAR STIFFNESS;

EID: 84927735917     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.116.303697     Document Type: Review

References (98)

1. White FN, Grollman A. Autoimmune factors associated with infarction of the kidney. Nephron. 1964;1:93-102.
2. Okuda T, Grollman A. Passive transfer of autoimmune induced hypertension in the rat by lymph node cells. Tex Rep Biol Med. 1967;25:257-264.
3. Olsen F. Type and course of the inflammatory cellular reaction in acute angiotensin-hypertensive vascular disease in rats. Acta Pathol Microbiol Scand A. 1970;78:143-150.
4. Olsen F. Inflammatory cellular reaction in hypertensive vascular disease in man. Acta Pathol Microbiol Scand A. 1972;80:253-256.
5. Takeichi N, Hamada J, Takimoto M, Fujiwara K, Kobayashi H. Depression of T cell-mediated immunity and enhancement of autoantibody production by natural infection with microorganisms in spontaneously hypertensive rats (SHR). Microbiol Immunol. 1988;32:1235-1244.
6. Takeichi N, Boone CW. Spontaneous rosette formation of rat thymus cells with guinea pig erythrocytes. Cell Immunol. 1976;27:52-59.
7. Purcell ES, Wood GW, Gattone VH II. Immune system of the spontaneously hypertensive rat: II. Morphology and function. Anat Rec. 1993;237:236-242. doi: 10.1002/ar.1092370211.
8. Bendich A, Belisle EH, Strausser HR. Immune system modulation and its effect on the blood pressure of the spontaneously hypertensive male and female rat. Biochem Biophys Res Commun. 1981;99:600-607.
9. Dzielak DJ. Immune mechanisms in experimental and essential hypertension. Am J Physiol. 1991;260:R459-R467.
10. Olsen F. Transfer of arterial hypertension by splenic cells from DOCA-salt hypertensive and renal hypertensive rats to normotensive recipients. Acta Pathol Microbiol Scand C. 1980;88:1-5.
11. Olofsson PS, Rosas-Ballina M, Levine YA, Tracey KJ. Rethinking inflammation: neural circuits in the regulation of immunity. Immunol Rev. 2012;248:188-204. doi: 10.1111/j.1600-065X.2012.01138.x.
12. Harwani SC, Chapleau MW, Legge KL, Ballas ZK, Abboud FM. Neurohormonal modulation of the innate immune system is proinflammatory in the prehypertensive spontaneously hypertensive rat, a genetic model of essential hypertension. Circ Res. 2012;111:1190-1197. doi: 10.1161/CIRCRESAHA.112.277475.
13. Hashimoto D, Chow A, Noizat C, et al. Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes. Immunity. 2013;38:792-804. doi: 10.1016/j. immuni.2013.04.004.
14. Jakubzick C, Gautier EL, Gibbings SL, et al. Minimal differentiation of classical monocytes as they survey steady-state tissues and transport antigen to lymph nodes. Immunity. 2013;39:599-610. doi: 10.1016/j. immuni.2013.08.007.
15. Vinh A, Chen W, Blinder Y, Weiss D, Taylor WR, Goronzy JJ, Weyand CM, Harrison DG, Guzik TJ. Inhibition and genetic ablation of the B7/CD28 T-cell costimulation axis prevents experimental hypertension. Circulation. 2010;122:2529-2537. doi: 10.1161/CIRCULATIONAHA.109.930446.
16. Boyman O, Purton JF, Surh CD, Sprent J. Cytokines and T-cell homeostasis. Curr Opin Immunol. 2007;19:320-326. doi: 10.1016/j. coi.2007.04.015.
17. Gutcher I, Becher B. APC-derived cytokines and T cell polarization in autoimmune inflammation. J Clin Invest. 2007;117:1119-1127. doi: 10.1172/JCI31720.
18. Abbas A, Lichtman A, Pillai S. Cellular and Molecular Immunology. 7th ed. Philadelphia, PA: Elsevier Saunders; 2010.
19. High KP, Akbar AN, Nikolich-Zugich J. Translational research in immune senescence: assessing the relevance of current models. Semin Immunol. 2012;24:373-382. doi: 10.1016/j.smim.2012.04.007.
20. Kared H, Camous X, Larbi A. T cells and their cytokines in persistent stimulation of the immune system. Curr Opin Immunol. 2014;29:79-85. doi: 10.1016/j.coi.2014.05.003.
21. Liuzzo G, Goronzy JJ, Yang H, Kopecky SL, Holmes DR, Frye RL, Weyand CM. Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes. Circulation. 2000;101:2883-2888.
22. Weyand CM, Yang Z, Goronzy JJ. T-cell aging in rheumatoid arthritis. Curr Opin Rheumatol. 2014;26:93-100. doi: 10.1097/ BOR.0000000000000011.
23. Youn JC, Yu HT, Lim BJ, Koh MJ, Lee J, Chang DY, Choi YS, Lee SH, Kang SM, Jang Y, Yoo OJ, Shin EC, Park S. Immunosenescent CD8+ T cells and C-X-C chemokine receptor type 3 chemokines are increased in human hypertension. Hypertension. 2013;62:126-133. doi: 10.1161/ HYPERTENSIONAHA.113.00689.
24. Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, Goronzy J, Weyand C, Harrison DG. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med. 2007;204:2449-2460. doi: 10.1084/jem.20070657.
25. Crowley SD, Song YS, Lin EE, Griffiths R, Kim HS, Ruiz P. Lymphocyte responses exacerbate angiotensin II-dependent hypertension. Am J Physiol Regul Integr Comp Physiol. 2010;298:R1089-R1097. doi: 10.1152/ ajpregu.00373.2009.
26. Mattson DL, Lund H, Guo C, Rudemiller N, Geurts AM, Jacob H. Genetic mutation of recombination activating gene 1 in Dahl salt-sensitive rats attenuates hypertension and renal damage. Am J Physiol Regul Integr Comp Physiol. 2013;304:R407-R414. doi: 10.1152/ajpregu.00304.2012.
27. Muller DN, Shagdarsuren E, Park JK, et al. Immunosuppressive treatment protects against angiotensin II-induced renal damage. Am J Pathol. 2002;161:1679-1693. doi: 10.1016/S0002-9440(10)64445-8.
28. Bravo Y, Quiroz Y, Ferrebuz A, Vaziri ND, Rodríguez-Iturbe B. Mycophenolate mofetil administration reduces renal inflammation, oxidative stress, and arterial pressure in rats with lead-induced hypertension. Am J Physiol Renal Physiol. 2007;293:F616-F623. doi: 10.1152/ ajprenal.00507.2006.
29. Franco M, Martínez F, Quiroz Y, Galicia O, Bautista R, Johnson RJ, Rodríguez-Iturbe B. Renal angiotensin II concentration and interstitial infiltration of immune cells are correlated with blood pressure levels in salt-sensitive hypertension. Am J Physiol Regul Integr Comp Physiol. 2007;293:R251-R256. doi: 10.1152/ajpregu.00645.2006.
30. Herrera J, Ferrebuz A, MacGregor EG, Rodriguez-Iturbe B. Mycophenolate mofetil treatment improves hypertension in patients with psoriasis and rheumatoid arthritis. J Am Soc Nephrol. 2006;17:S218-S225. doi: 10.1681/ASN.2006080918.
31. De Ciuceis C, Amiri F, Brassard P, Endemann DH, Touyz RM, Schiffrin EL. Reduced vascular remodeling, endothelial dysfunction, and oxidative stress in resistance arteries of angiotensin II-infused macrophage colonystimulating factor-deficient mice: evidence for a role in inflammation in angiotensin-induced vascular injury. Arterioscler Thromb Vasc Biol. 2005;25:2106-2113. doi: 10.1161/01.ATV.0000181743.28028.57.
32. Ko EA, Amiri F, Pandey NR, Javeshghani D, Leibovitz E, Touyz RM, Schiffrin EL. Resistance artery remodeling in deoxycorticosterone acetate-salt hypertension is dependent on vascular inflammation: evidence from m-CSF-deficient mice. Am J Physiol Heart Circ Physiol. 2007;292:H1789-H1795. doi: 10.1152/ajpheart.01118.2006.
33. Wenzel P, Knorr M, Kossmann S, et al. Lysozyme M-positive monocytes mediate angiotensin II-induced arterial hypertension and vascular dysfunction. Circulation. 2011;124:1370-1381. doi: 10.1161/ CIRCULATIONAHA.111.034470.
34. Gu C, Wu L, Li X. IL-17 family: cytokines, receptors and signaling. Cytokine. 2013;64:477-485. doi: 10.1016/j.cyto.2013.07.022.
35. Gaffen SL. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol. 2009;9:556-567. doi: 10.1038/nri2586.
36. Sharma AK, Mulloy DP, Le LT, Laubach VE. NADPH oxidase mediates synergistic effects of IL-17 and TNF-α on CXCL1 expression by epithelial cells after lung ischemia-reperfusion. Am J Physiol Lung Cell Mol Physiol. 2014;306:L69-L79. doi: 10.1152/ajplung.00205.2013.
37. Madhur MS, Lob HE, McCann LA, Iwakura Y, Blinder Y, Guzik TJ, Harrison DG. Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction. Hypertension. 2010;55:500-507. doi: 10.1161/HYPERTENSIONAHA.109.145094.
38. Langley RG, Elewski BE, Lebwohl M, et al; ERASURE Study Group; FIXTURE Study Group. Secukinumab in plaque psoriasis-results of two phase 3 trials. N Engl J Med. 2014;371:326-338. doi: 10.1056/ NEJMoa1314258.
39. Mease PJ, Genovese MC, Greenwald MW, Ritchlin CT, Beaulieu AD, Deodhar A, Newmark R, Feng J, Erondu N, Nirula A. Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N Engl J Med. 2014;370:2295-2306. doi: 10.1056/NEJMoa1315231.
40. Fleming I, Fisslthaler B, Dimmeler S, Kemp BE, Busse R. Phosphorylation of Thr(495) regulates Ca(2+)/calmodulin-dependent endothelial nitric oxide synthase activity. Circ Res. 2001;88:E68-E75.
41. Piazza M, Taiakina V, Guillemette SR, Guillemette JG, Dieckmann T. Solution structure of calmodulin bound to the target peptide of endothelial nitric oxide synthase phosphorylated at Thr495. Biochemistry. 2014;53:1241-1249. doi: 10.1021/bi401466s.
42. Amador CA, Barrientos V, Peña J, Herrada AA, González M, Valdés S, Carrasco L, Alzamora R, Figueroa F, Kalergis AM, Michea L. Spironolactone decreases DOCA-salt-induced organ damage by blocking the activation of T helper 17 and the downregulation of regulatory T lymphocytes. Hypertension. 2014;63:797-803. doi: 10.1161/ HYPERTENSIONAHA.113.02883.
43. Wu J, Thabet SR, Kirabo A, Trott DW, Saleh MA, Xiao L, Madhur MS, Chen W, Harrison DG. Inflammation and mechanical stretch promote aortic stiffening in hypertension through activation of p38 mitogenactivated protein kinase. Circ Res. 2014;114:616-625. doi: 10.1161/ CIRCRESAHA.114.302157.
44. Santner-Nanan B, Peek MJ, Khanam R, Richarts L, Zhu E, Fazekas de St Groth B, Nanan R. Systemic increase in the ratio between Foxp3+ and IL- 17-producing CD4+ T cells in healthy pregnancy but not in preeclampsia. J Immunol. 2009;183:7023-7030. doi: 10.4049/jimmunol.0901154.
45. Toldi G, Rigó J Jr, Stenczer B, Vásárhelyi B, Molvarec A. Increased prevalence of IL-17-producing peripheral blood lymphocytes in pre-eclampsia. Am J Reprod Immunol. 2011;66:223-229. doi: 10.1111/j.1600-0897.2011.00987.x.
46. Cornelius DC, Hogg JP, Scott J, Wallace K, Herse F, Moseley J, Wallukat G, Dechend R, LaMarca B. Administration of interleukin-17 soluble receptor C suppresses TH17 cells, oxidative stress, and hypertension in response to placental ischemia during pregnancy. Hypertension. 2013;62:1068-1073. doi: 10.1161/HYPERTENSIONAHA.113.01514.
47. Krebs CF, Lange S, Niemann G, Rosendahl A, Lehners A, Meyer- Schwesinger C, Stahl RA, Benndorf RA, Velden J, Paust HJ, Panzer U, Ehmke H, Wenzel UO. Deficiency of the interleukin 17/23 axis accelerates renal injury in mice with deoxycorticosterone acetate+angiotensin ii-induced hypertension. Hypertension. 2014;63:565-571. doi: 10.1161/ HYPERTENSIONAHA.113.02620.
48. Ishimitsu T, Uehara Y, Numabe A, Tsukada H, Ogawa Y, Iwai J, Ikeda T, Matsuoka H, Sugimoto T, Yagi S. Interferon gamma attenuates hypertensive renal injury in salt-sensitive Dahl rats. Hypertension. 1992;19:804-808.
49. Garcia AG, Wilson RM, Heo J, Murthy NR, Baid S, Ouchi N, Sam F. Interferon-λ ablation exacerbates myocardial hypertrophy in diastolic heart failure. Am J Physiol Heart Circ Physiol. 2012;303:H587-H596. doi: 10.1152/ajpheart.00298.2012.
50. Saleh M, McMaster WG, Wu J, Norlander AE, Funt SA, Thabet SR, Kirabo A, Xiao L, Chen W, Itani H, Michell D, Huan T, Zhang Y, Takaki S, Titze JM, Levy D, Harrison DG, Madhur MS. Lymphocyte adaptor protein LNK deficiency exacerbates hypertension and end-organ inflammation [published online ahead of print February 9, 2015]. J Clin Invest. doi: 10.1172. http://www.jci.org/articles/view/76327.
51. Markó L, Kvakan H, Park JK, Qadri F, Spallek B, Binger KJ, Bowman EP, Kleinewietfeld M, Fokuhl V, Dechend R, Müller DN. Interferon-λ signaling inhibition ameliorates angiotensin II-induced cardiac damage. Hypertension. 2012;60:1430-1436. doi: 10.1161/ HYPERTENSIONAHA.112.199265.
52. Jain S, Shah M, Li Y, Vinukonda G, Sehgal PB, Kumar A. Upregulation of human angiotensinogen (AGT) gene transcription by interferon-gamma: involvement of the STAT1-binding motif in the AGT promoter. Biochim Biophys Acta. 2006;1759:340-347. doi: 10.1016/j.bbaexp.2006.07.003.
53. Satou R, Miyata K, Gonzalez-Villalobos RA, Ingelfinger JR, Navar LG, Kobori H. Interferon-λ biphasically regulates angiotensinogen expression via a JAK-STAT pathway and suppressor of cytokine signaling 1 (SOCS1) in renal proximal tubular cells. FASEB J. 2012;26:1821-1830. doi: 10.1096/fj.11-195198.
54. Kobori H, Nangaku M, Navar LG, Nishiyama A. The intrarenal reninangiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev. 2007;59:251-287. doi: 10.1124/ pr.59.3.3.
55. Kamat NV, Thabet SR, Xiao L, Saleh MA, Kirabo A, Madhur MS, Delpire E, Harrison DG, McDonough AA. Renal transporter activation during angiotensin-II hypertension is blunted in interferon-gamma-/- and interleukin-17A-/- Mice. Hypertension. 2015;65:569-576. doi: 10.1161/ HYPERTENSIONAHA.114.04975.
56. Kleinbongard P, Heusch G, Schulz R. TNFalpha in atherosclerosis, myocardial ischemia/reperfusion and heart failure. Pharmacol Ther. 2010;127:295-314. doi: 10.1016/j.pharmthera.2010.05.002.
57. Landry DB, Couper LL, Bryant SR, Lindner V. Activation of the NFkappa B and I kappa B system in smooth muscle cells after rat arterial injury. Induction of vascular cell adhesion molecule-1 and monocyte chemoattractant protein-1. Am J Pathol. 1997;151:1085-1095.
58. Neumann P, Gertzberg N, Johnson A. TNF-alpha induces a decrease in eNOS promoter activity. Am J Physiol Lung Cell Mol Physiol. 2004;286:L452-L459. doi: 10.1152/ajplung.00378.2002.
59. Alonso J, Sánchez de Miguel L, Montón M, Casado S, López-Farré A. Endothelial cytosolic proteins bind to the 3' untranslated region of endothelial nitric oxide synthase mRNA: regulation by tumor necrosis factor alpha. Mol Cell Biol. 1997;17:5719-5726.
60. Sun HX, Zeng DY, Li RT, Pang RP, Yang H, Hu YL, Zhang Q, Jiang Y, Huang LY, Tang YB, Yan GJ, Zhou JG. Essential role of microRNA-155 in regulating endothelium-dependent vasorelaxation by targeting endothelial nitric oxide synthase. Hypertension. 2012;60:1407-1414. doi: 10.1161/ HYPERTENSIONAHA.112.197301.
61. Ramseyer VD, Garvin JL. Tumor necrosis factor-α: regulation of renal function and blood pressure. Am J Physiol Renal Physiol. 2013;304:F1231-F1242. doi: 10.1152/ajprenal.00557.2012.
62. Ramseyer VD, Hong NJ, Garvin JL. Tumor necrosis factor α decreases nitric oxide synthase type 3 expression primarily via Rho/Rho kinase in the thick ascending limb. Hypertension. 2012;59:1145-1150. doi: 10.1161/ HYPERTENSIONAHA.111.189761.
63. Garvin JL, Herrera M, Ortiz PA. Regulation of renal NaCl transport by nitric oxide, endothelin, and ATP: clinical implications. Annu Rev Physiol. 2011;73:359-376. doi: 10.1146/annurev-physiol-012110-142247.
64. Dickhout JG, Mori T, Cowley AW Jr. Tubulovascular nitric oxide crosstalk: buffering of angiotensin II-induced medullary vasoconstriction. Circ Res. 2002;91:487-493.
65. Irani RA, Zhang Y, Zhou CC, Blackwell SC, Hicks MJ, Ramin SM, Kellems RE, Xia Y. Autoantibody-mediated angiotensin receptor activation contributes to preeclampsia through tumor necrosis factoralpha signaling. Hypertension. 2010;55:1246-1253. doi: 10.1161/ HYPERTENSIONAHA.110.150540.
66. Venegas-Pont M, Manigrasso MB, Grifoni SC, LaMarca BB, Maric C, Racusen LC, Glover PH, Jones AV, Drummond HA, Ryan MJ. Tumor necrosis factor-alpha antagonist etanercept decreases blood pressure and protects the kidney in a mouse model of systemic lupus erythematosus. Hypertension. 2010;56:643-649. doi: 10.1161/ HYPERTENSIONAHA.110.157685.
67. Elmarakby AA, Quigley JE, Imig JD, Pollock JS, Pollock DM. TNFalpha inhibition reduces renal injury in DOCA-salt hypertensive rats. Am J Physiol Regul Integr Comp Physiol. 2008;294:R76-R83. doi: 10.1152/ ajpregu.00466.2007.
68. Tran LT, MacLeod KM, McNeill JH. Chronic etanercept treatment prevents the development of hypertension in fructose-fed rats. Mol Cell Biochem. 2009;330:219-228. doi: 10.1007/s11010-009-0136-z.
69. Sriramula S, Haque M, Majid DS, Francis J. Involvement of tumor necrosis factor-alpha in angiotensin II-mediated effects on salt appetite, hypertension, and cardiac hypertrophy. Hypertension. 2008;51:1345-1351. doi: 10.1161/HYPERTENSIONAHA.107.102152.
70. Mäki-Petäjä KM, Elkhawad M, Cheriyan J, Joshi FR, Ostör AJ, Hall FC, Rudd JH, Wilkinson IB. Anti-tumor necrosis factor-α therapy reduces aortic inflammation and stiffness in patients with rheumatoid arthritis. Circulation. 2012;126:2473-2480. doi: 10.1161/ CIRCULATIONAHA.112.120410.
71. Mathieu S, Pereira B, Couderc M, Rabois E, Dubost JJ, Soubrier M. No significant changes in arterial stiffness in patients with ankylosing spondylitis after tumour necrosis factor alpha blockade treatment for 6 and 12 months. Rheumatology (Oxford). 2013;52:204-209. doi: 10.1093/ rheumatology/kes272.
72. Rincon M. Interleukin-6: from an inflammatory marker to a target for inflammatory diseases. Trends Immunol. 2012;33:571-577. doi: 10.1016/j. it.2012.07.003.
73. Roche NE, Fulbright JW, Wagner AD, Hunder GG, Goronzy JJ, Weyand CM. Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis. Arthritis Rheum. 1993;36:1286-1294.
74. Ogata A, Tanaka T. Tocilizumab for the treatment of rheumatoid arthritis and other systemic autoimmune diseases: current perspectives and future directions. Int J Rheumatol. 2012;2012:946048. doi: 10.1155/2012/946048.
75. Vázquez-Oliva G, Fernández-Real JM, Zamora A, Vilaseca M, Badimón L. Lowering of blood pressure leads to decreased circulating interleukin- 6 in hypertensive subjects. J Hum Hypertens. 2005;19:457-462. doi: 10.1038/sj.jhh.1001845.
76. Luther JM, Gainer JV, Murphey LJ, Yu C, Vaughan DE, Morrow JD, Brown NJ. Angiotensin II induces interleukin-6 in humans through a mineralocorticoid receptor-dependent mechanism. Hypertension. 2006;48:1050-1057. doi: 10.1161/01.HYP.0000248135.97380.76.
77. Lee DL, Sturgis LC, Labazi H, Osborne JB Jr, Fleming C, Pollock JS, Manhiani M, Imig JD, Brands MW. Angiotensin II hypertension is attenuated in interleukin-6 knockout mice. Am J Physiol Heart Circ Physiol. 2006;290:H935-H940. doi: 10.1152/ajpheart.00708.2005.
78. Li K, Guo D, Zhu H, Hering-Smith KS, Hamm LL, Ouyang J, Dong Y. Interleukin-6 stimulates epithelial sodium channels in mouse cortical collecting duct cells. Am J Physiol Regul Integr Comp Physiol. 2010;299:R590-R595. doi: 10.1152/ajpregu.00207.2009.
79. Fiorentino DF, Bond MW, Mosmann TR. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med. 1989;170:2081-2095.
80. Sabat R, Grütz G, Warszawska K, Kirsch S, Witte E, Wolk K, Geginat J. Biology of interleukin-10. Cytokine Growth Factor Rev. 2010;21:331-344. doi: 10.1016/j.cytogfr.2010.09.002.
81. Timasheva YR, Nasibullin TR, Zakirova AN, Mustafina OE. Association of interleukin-6, interleukin-12, and interleukin-10 gene polymorphisms with essential hypertension in Tatars from Russia. Biochem Genet. 2008;46:64-74. doi: 10.1007/s10528-007-9130-x.
82. Didion SP, Kinzenbaw DA, Schrader LI, Chu Y, Faraci FM. Endogenous interleukin-10 inhibits angiotensin II-induced vascular dysfunction. Hypertension. 2009;54:619-624. doi: 10.1161/ HYPERTENSIONAHA.109.137158.
83. Hennessy A, Pilmore HL, Simmons LA, Painter DM. A deficiency of placental IL-10 in preeclampsia. J Immunol. 1999;163:3491-3495.
84. Tinsley JH, South S, Chiasson VL, Mitchell BM. Interleukin-10 reduces inflammation, endothelial dysfunction, and blood pressure in hypertensive pregnant rats. Am J Physiol Regul Integr Comp Physiol. 2010;298:R713-R719. doi: 10.1152/ajpregu.00712.2009.
85. Lai Z, Kalkunte S, Sharma S. A critical role of interleukin-10 in modulating hypoxia-induced preeclampsia-like disease in mice. Hypertension. 2011;57:505-514. doi: 10.1161/HYPERTENSIONAHA.110.163329.
86. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350:672-683. doi: 10.1056/NEJMoa031884.
87. Barhoumi T, Kasal DA, Li MW, Shbat L, Laurant P, Neves MF, Paradis P, Schiffrin EL. T regulatory lymphocytes prevent angiotensin II-induced hypertension and vascular injury. Hypertension. 2011;57:469-476. doi: 10.1161/HYPERTENSIONAHA.110.162941.
88. Matrougui K, Abd Elmageed Z, Zakaria AE, Kassan M, Choi S, Nair D, Gonzalez-Villalobos RA, Chentoufi AA, Kadowitz P, Belmadani S, Partyka M. Natural regulatory T cells control coronary arteriolar endothelial dysfunction in hypertensive mice. Am J Pathol. 2011;178:434-441. doi: 10.1016/j.ajpath.2010.11.034.
89. Kvakan H, Kleinewietfeld M, Qadri F, Park JK, Fischer R, Schwarz I, Rahn HP, Plehm R, Wellner M, Elitok S, Gratze P, Dechend R, Luft FC, Muller DN. Regulatory T cells ameliorate angiotensin II-induced cardiac damage. Circulation. 2009;119:2904-2912. doi: 10.1161/ CIRCULATIONAHA.108.832782.
90. Kasal DA, Barhoumi T, Li MW, Yamamoto N, Zdanovich E, Rehman A, Neves MF, Laurant P, Paradis P, Schiffrin EL. T regulatory lymphocytes prevent aldosterone-induced vascular injury. Hypertension. 2012;59:324-330. doi: 10.1161/HYPERTENSIONAHA.111.181123.
91. Kassan M, Galan M, Partyka M, Trebak M, Matrougui K. Interleukin-10 released by CD4(+)CD25(+) natural regulatory T cells improves microvascular endothelial function through inhibition of NADPH oxidase activity in hypertensive mice. Arterioscler Thromb Vasc Biol. 2011;31:2534-2542. doi: 10.1161/ATVBAHA.111.233262.
92. Viel EC, Lemarié CA, Benkirane K, Paradis P, Schiffrin EL. Immune regulation and vascular inflammation in genetic hypertension. Am J Physiol Heart Circ Physiol. 2010;298:H938-H944. doi: 10.1152/ajpheart.00707.2009.
93. Kirabo A, Fontana V, de Faria APC, et al. DC isoketal-modified proteins activate T cells and promote hypertension. J Clin Invest. 2014;124:4642-4656. doi: 10.1172/JCI74084.
94. Rajagopalan S, Kurz S, Münzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DG. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest. 1996;97:1916-1923. doi: 10.1172/JCI118623.
95. Somers MJ, Mavromatis K, Galis ZS, Harrison DG. Vascular superoxide production and vasomotor function in hypertension induced by deoxycorticosterone acetate-salt. Circulation. 2000;101:1722-1728.
96. Miyashita H, Chikazawa M, Otaki N, Hioki Y, Shimozu Y, Nakashima F, Shibata T, Hagihara Y, Maruyama S, Matsumi N, Uchida K. Lysine pyrrolation is a naturally-occurring covalent modification involved in the production of DNA mimic proteins. Sci Rep. 2014;4:5343. doi: 10.1038/srep05343.
97. Guyton AC. Abnormal renal function and autoregulation in essential hypertension. Hypertension. 1991;18:III49-III53.
98. Shi P, Diez-Freire C, Jun JY, Qi Y, Katovich MJ, Li Q, Sriramula S, Francis J, Sumners C, Raizada MK. Brain microglial cytokines in neurogenic hypertension. Hypertension. 2010;56:297-303. doi: 10.1161/ HYPERTENSIONAHA.110.150409.